标题
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
作者
关键词
-
出版物
Molecular Cancer
Volume 19, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-05-02
DOI
10.1186/s12943-020-01200-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
- (2019) Akinori Sasaki et al. Gastric Cancer
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs
- (2019) Betul Gok Yavuz et al. Scientific Reports
- Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
- (2019) James B. Wing et al. IMMUNITY
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Capturing Hyperprogressive disease with immune checkpoint inhibitors using RECIST 1.1 criteria
- (2019) Ignacio Matos et al. CLINICAL CANCER RESEARCH
- Blockage of immune checkpoint molecules increases T‐cell priming potential of dendritic cell vaccine
- (2019) Hadi Hassannia et al. IMMUNOLOGY
- The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review
- (2019) Elissar Moujaess et al. Immunotherapy
- Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
- (2019) Samuel J. Klempner et al. ONCOLOGIST
- Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies
- (2019) Tom J. Harryvan et al. Journal of Clinical Medicine
- The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma
- (2018) Anne M. Mills et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review
- (2018) Feifei Teng et al. CANCER LETTERS
- Nivolumab in squamous cell carcinoma of the head and neck
- (2018) Pol Specenier Expert Review of Anticancer Therapy
- IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling
- (2018) Yi Gao et al. INTERNATIONAL JOURNAL OF CANCER
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- (2018) James Larkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- (2018) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma
- (2018) Yusheng Cheng et al. Cell Death & Disease
- Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
- (2018) Rebekka Weber et al. Frontiers in Immunology
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
- (2018) Derin B. Keskin et al. NATURE
- Hyperprogressive disease: recognizing a novel pattern to improve patient management
- (2018) Stéphane Champiat et al. Nature Reviews Clinical Oncology
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
- (2018) Giuseppe Lo Russo et al. CLINICAL CANCER RESEARCH
- Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma
- (2017) Sun Hye Kim et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
- (2017) Gustavo Schvartsman et al. LUNG CANCER
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death
- (2017) Emarndeena H Cheteh et al. Cell Death & Disease
- Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer
- (2017) Kenji Gonda et al. Oncology Letters
- Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells
- (2017) Paul E. Clavijo et al. Oncotarget
- Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy
- (2017) Daiki Ogawara et al. Thoracic Cancer
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Intracellular signalling pathways: targets to reverse immunosenescence
- (2016) T. Fulop et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
- (2016) M. Sade-Feldman et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Efficacy of PD-1 blockade in tumors with MMR deficiency
- (2016) Valerie Lee et al. Immunotherapy
- Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy
- (2016) Gregory S. Alexander et al. Journal of Hematology & Oncology
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation
- (2016) J-t Cheng et al. Oncogenesis
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
- (2016) Ruea-Yea Huang et al. OncoImmunology
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer associated fibroblasts have phenotypic and functional characteristics similar to the fibrocytes that represent a novel MDSC subset
- (2015) Gurcan Gunaydin et al. OncoImmunology
- Mechanisms of resistance to EGFR tyrosine kinase inhibitors
- (2015) Lihua Huang et al. Acta Pharmaceutica Sinica B
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
- (2014) S. Nag et al. CURRENT MEDICINAL CHEMISTRY
- Regulation of the anti-tumour immune response by cancer-associated fibroblasts
- (2014) James Harper et al. SEMINARS IN CANCER BIOLOGY
- Depletion of Tumor-Associated Macrophages Slows the Growth of Chemically Induced Mouse Lung Adenocarcinomas
- (2014) Jason M. Fritz et al. Frontiers in Immunology
- Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
- (2014) Saskia JAM Santegoets et al. Journal for ImmunoTherapy of Cancer
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
- (2013) P. A. Ascierto et al. CLINICAL CANCER RESEARCH
- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells
- (2013) B. Weide et al. CLINICAL CANCER RESEARCH
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
- (2013) M. Nishino et al. CLINICAL CANCER RESEARCH
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- The Effect of Age on Thymic Function
- (2013) Donald B. Palmer Frontiers in Immunology
- Human T Cell Aging and the Impact of Persistent Viral Infections
- (2013) T. Fülöp et al. Frontiers in Immunology
- A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells
- (2011) S. Solito et al. BLOOD
- MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis
- (2011) Yan Wan et al. BMC CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Maximizing Tumor Immunity With Fractionated Radiation
- (2011) Dörthe Schaue et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- How do Regulatory T Cells Work?
- (2009) A. Corthay SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation
- (2008) Y. Onishi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search